| Active substance | pembrolizumab |
| Holder | MSD Belgium BV/SRL |
| Status | closed |
| Indication | in combination with chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery for the treatment of adults with locally advanced, or early-stage triple-negative breast cancer at high risk of recurrence |
| Public documents | Approbation |
| Information for the patient | |
| Informed Consent | |
| Last update | 09/06/2022 |